Subscribe for relevant insights delivered straight to your inbox
Corporate credits have suffered during the COVID-19 outbreak, but history shows that these bonds have performed well in the years after a significant drawdown.
The importance of staying active to navigate the downturn and position for an eventual recovery.
How the coronavirus pandemic is shining a spotlight on the long-term potential of health care’s advanced research and technology.
A discussion of the recent actions taken by the U.S. Federal Reserve to improve liquidity in money markets.
Three steps investors can take today to navigate the current environment.
We see reason to remain optimistic in 2020 by focusing on companies whose business models support a sustainable global economy.
Nick Maroutsos explains why the Fed’s refusal to address structural flaws in short-term lending markets risks a repeat of September’s repo market volatility.
After a volatile 2019, what can health care investors expect in the new year?
As equity multiples climb, we believe investors should focus on high-quality value or cyclical stocks to help minimize risk.
Signs of a slight uptick in global economic growth next year are emerging. Should the growth materialize, we think stocks could benefit.
There’s more than one way to gain exposure to advances in oncology, say Andy Acker, Dan Lyons and Luyi Guo of the Global Life Sciences Team.
